About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Atlanta | 370 Studies

Clinical Trials LymphomaAtlanta

Lymphoma Clinical Trials in Atlanta

Find 370 clinical trials for lymphoma near Atlanta, Georgia. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Atlanta

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 121-140 of 370 trials

TerminatedStudy of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) SubjectsA study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155NCT00498914·Beverly Hills, California and 21 others CompletedMORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaThis phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.NCT01748721·Birmingham, Alabama and 19 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingEpcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaThis phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to…NCT07365306·Duarte, California and 2 others

CompletedLenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaThis phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned…NCT02568553·Birmingham, Alabama and 23 others

RecruitingTesting the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaThis phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in…NCT04803201·Little Rock, Arkansas and 95 others

CompletedA Study Of PF-05082566 As A Single Agent And In Combination With RituximabA study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20…NCT01307267·Duarte, California and 41 others

RecruitingTesting Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaThis phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell…NCT05976763·Little Rock, Arkansas and 237 others

TerminatedAn Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesThis is an open-label study of INCB047986 given to two distinct groups of patients (Group 1 and Group 2) with advanced malignancies.NCT01929941·Atlanta, Georgia and 2 others

RecruitingA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasThe purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of…NCT04104776·Tampa, Florida and 79 others

CompletedEfficacy and Safety Study of Fostamatinib Tablets to Treat B-cell LymphomaPatients: B-cell lymphoma, refractory, diffuse, nodular, mantle, other Phase I : Two groups of 6 patients, escalating dose tolerability- 28 days Phase II: Three groups of 16…NCT00446095·Los Angeles, California and 10 others

CompletedA Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesTo assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered…NCT03106428·Los Angeles, California and 13 others

Active not recruitingStudying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaThis phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with…NCT05602194·Birmingham, Alabama and 227 others

CompletedRituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)This study is designed as a Phase III, multicenter trial, comparing progression-free survival (PFS) after autologous hematopoietic stem cell transplantation using a standard…NCT00329030·New Haven, Connecticut and 35 others

CompletedTotal-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerThis phase I/II trial studies whether a new kind of blood stem cell (bone marrow) transplant, that may be less toxic, is able to treat underlying blood cancer.NCT00027820·Tucson, Arizona and 9 others

Active not recruitingVorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow TransplantationThe purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow…NCT03842696·Aurora, Colorado and 6 others

CompletedPlatform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).NCT03527147·Los Angeles, California and 11 others

Active not recruitingStudy to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaThe purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455)…NCT04756726·Phoenix, Arizona and 12 others

TerminatedNKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaThis study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large…NCT05664217·La Jolla, California and 21 others

CompletedDose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P MutationRecent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B…NCT02252146·Los Angeles, California and 11 others

CompletedA Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with…NCT03372057·Duarte, California and 35 others

PreviousPage 7 of 19Next

Other Conditions in Atlanta

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia